Regorafenib Dose Optimization Study (ReDOS): Randomized Phase II Trial to Evaluate Dosing Strategies for Regorafenib in Refractory Metastatic Colorectal Cancer-An ACCRU Network Study

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2018年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9 / 10
页数：2
相关论文
共 50 条
  • [1] Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC) (a)over-cap(sic) An ACCRU Network study.
    Bekaii-Saab, Tanios S.
    Ou, Fang-Shu
    Anderson, Daniel M.
    Ahn, Daniel H.
    Boland, Patrick Mckay
    Ciombor, Kristen Keon
    Jacobs, Nisha Lassi
    Desnoyers, Rodwige J.
    Cleary, James M.
    Meyers, Jeffrey P.
    Chiorean, E. Gabriela
    Pedersen, Katrina
    Barzi, Afsaneh
    Sloan, Jeffrey
    McCune, Jeannine S.
    Lacouture, Mario E.
    Lenz, Heinz Josef
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [2] Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) - An ACCRU Network study
    Bekaii-Saab, T.
    Ou, F.
    Anderson, D.
    Ahn, D.
    Boland, P.
    Ciombor, K.
    Jacobs, N.
    Desnoyers, R.
    Cleary, J.
    Meyers, J.
    Chiorean, E.
    Pedersen, K.
    Barzi, A.
    Sloan, J.
    McCune, J.
    Lacouture, M.
    Lenz, H.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 105 - 105
  • [3] Regorafenib dose optimization study (ReDOS): A phase II randomized study of lower starting dose regorafenib compared to standard dose regorafenib in patients with refractory metastatic colorectal cancer (mCRC)
    Bekaii-Saab, Tanios S.
    Ou, Fang-Shu
    Ciombor, Kristen Keon
    Farhat, Mohamed I.
    Kirshner, Jeffrey J.
    Knost, James A.
    Anderson, Daniel M.
    Soori, Gamini S.
    Boland, Patrick Mckay
    Wender, Donald B.
    Desnoyers, Rodwige J.
    Sargent, Daniel J.
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
    Bekaii-Saab, Tanios S.
    Ou, Fang-Shu
    Ahn, Daniel H.
    Boland, Patrick M.
    Ciombor, Kristen K.
    Heying, Erica N.
    Dockter, Travis J.
    Jacobs, Nisha L.
    Pasche, Boris C.
    Cleary, James M.
    Meyers, Jeffrey P.
    Desnoyers, Rodwige J.
    McCune, Jeannines
    Pedersen, Katrina
    Barzi, Afsaneh
    Chiorean, E. Gabriela
    Sloan, Jeffrey
    Lacouture, Mario E.
    Lenz, Heinz-Josef
    Grothey, Axel
    LANCET ONCOLOGY, 2019, 20 (08): : 1070 - 1082
  • [5] Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer
    Kato, Takeshi
    Kudo, Toshihiro
    Kagawa, Yoshinori
    Murata, Kohei
    Ota, Hirofumi
    Noura, Shingo
    Hasegawa, Junichi
    Tamagawa, Hiroshi
    Ohta, Katsuya
    Ikenaga, Masakazu
    Miyazaki, Susumu
    Komori, Takamichi
    Uemura, Mamoru
    Nishimura, Junichi
    Hata, Taishi
    Matsuda, Chu
    Satoh, Taroh
    Mizushima, Tsunekazu
    Ohno, Yuko
    Yamamoto, Hirofumi
    Doki, Yuichiro
    Eguchi, Hidetoshi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [6] Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer
    Takeshi Kato
    Toshihiro Kudo
    Yoshinori Kagawa
    Kohei Murata
    Hirofumi Ota
    Shingo Noura
    Junichi Hasegawa
    Hiroshi Tamagawa
    Katsuya Ohta
    Masakazu Ikenaga
    Susumu Miyazaki
    Takamichi Komori
    Mamoru Uemura
    Junichi Nishimura
    Taishi Hata
    Chu Matsuda
    Taroh Satoh
    Tsunekazu Mizushima
    Yuko Ohno
    Hirofumi Yamamoto
    Yuichiro Doki
    Hidetoshi Eguchi
    Scientific Reports, 13
  • [7] Regorafenib dose escalation therapy for patients with refractory metastatic colorectal cancer (RECC Study)
    Nakamura, Masato
    Yamada, Takeshi
    Ishiyama, Shun
    Enomoto, Masanobu
    Yokomizo, Hajime
    Kosugi, Chihiro
    Sonoda, Hiromichi
    Ishimaru, Kei
    Ishibashi, Keiichiro
    Kuramochi, Hidekazu
    Nozawa, Keijiro
    Ohta, Ryo
    Takahashi, Makoto
    Yoshida, Hiroshi
    Hashiguchi, Yojiro
    Hirata, Keiji
    Katsumata, Kenji
    Ishida, Hideyuki
    Koda, Keiji
    Sakamoto, Kazuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [8] Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND)
    Bozzarelli, Silvia
    Rimassa, Lorenza
    Giordano, Laura
    Sala, Simona
    Tronconi, Maria Chiara
    Pressiani, Tiziana
    Smiroldo, Valeria
    Prete, Maria G.
    Spaggiari, Paola
    Personeni, Nicola
    Santoro, Armando
    FUTURE ONCOLOGY, 2019, 15 (35) : 4009 - 4017
  • [9] Phase II study of ruxolitinib with regorafenib for relapsed/refractory (r/r) metastatic colorectal cancer (mCRC).
    Fogelman, David R.
    Kochenderfer, Mark D.
    Saylors, Gene Brian
    Braiteh, Fadi S.
    Nemunaitis, John J.
    Cohn, Allen Lee
    O'Neill, Peter
    Zhou, Li
    Switzky, Julie C.
    Assad, Albert
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Phase II study on starting with reduced dose of regorafenib for metastatic colorectal cancer after standard chemotherapy
    Ota, Hirofumi
    Kagawa, Yoshinori
    Ohta, Katsuya
    Miyazaki, Susumu
    Hamabe, Atsushi
    Nishimura, Junichi
    Hata, Taishi
    Matsuda, Chu
    Mizushima, Tsunekazu
    Yamamoto, Hirofumi
    Doki, Yuichiro
    Mori, Masaki
    CANCER SCIENCE, 2018, 109 : 307 - 307
12345